Qure N.V. (NASDAQ:QURE) surged around 15% in early trading on Friday after the company said it has secured a Type A meeting ...

Shares of UniQure were higher after the gene therapy company said it had scheduled a Type A meeting with the Food and Drug Administration to discuss a Biologics License Application for the company's ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the ...

Families with Huntington’s need this to be true more than most. The devastating neurodegenerative disease is caused by a CAG ...

For the first time, scientists have successfully treated someone suffering from Huntington's disease, a fatal genetic illness ...

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

Researchers have implicated a new gene in the progression of Huntington's disease in a brain organoid model. The gene may contribute to brain abnormalities much earlier than previously thought. Six ...

UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...

Investing.com -- uniQure N.V. (NASDAQ:QURE) stock rose 15% Friday morning after the gene therapy company announced a scheduled Type A meeting with the U.S. Food and Drug Administration (FDA) to ...

LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSß Unique mechanism of action with potential to slow or stop ...

Huntington's Disease burdens caregivers in India, facing financial strain and limited support amid widespread underdiagnosis ...